Gestational Trophoblastic Disease Global Market Report 2024

The gestational trophoblastic disease market size has grown strongly in recent years. It will grow from $1.96 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period can be attributed to public health initiatives, an enhanced understanding of disease pathology, advancements in medical research and clinical trials, the development of targeted therapies, and a shift in treatment protocols.

The gestational trophoblastic disease market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to healthcare infrastructure development, the advancement of telemedicine and remote care, the adoption of patient-centric care approaches, regulatory approvals for novel treatments, and the progress in genomic and molecular studies. Major trends expected in the forecast period include a shift towards personalized medicine, advancements in molecular diagnostics, a focus on immunotherapies and targeted therapies, the integration of digital health technologies, and the rise of awareness and education programs.

The gestational trophoblastic disease market is anticipated to witness growth due to the increasing prevalence of abnormal pregnancies. Abnormal pregnancies, deviating from the typical course, pose health risks to both the mother and the fetus, potentially leading to gestational trophoblastic disease, especially in cases such as molar pregnancies. For instance, Gov.UK reported a 1.73% increase in reported abortions in Great Britain from 2020 to 2021, with around 25% of all pregnancies ending in abortion. This surge in abnormal pregnancies, as indicated by the rising abortion rates, is a key driver for the gestational trophoblastic disease market.

The growth of the gestational trophoblastic disease market is further fueled by the increasing prevalence of cigarette smoking. Cigarette smoking, known for its harmful effects, is linked to the development of gestational trophoblastic disease. The chemicals in tobacco smoke can damage trophoblastic cell DNA, leading to abnormal growth and division and the onset of gestational trophoblastic disease. For example, Statistics Canada reported a notable 45.2% increase in cigarette production in Canada from August 2021 to August 2022. The concurrent rise in cigarette consumption reinforces the association between smoking and gestational trophoblastic disease, contributing to market growth.

The gestational trophoblastic disease market faces challenges due to low awareness and diagnosis rates. Limited knowledge among healthcare professionals and individuals may result in delayed or missed diagnoses of gestational trophoblastic disease, impacting timely intervention and patient outcomes. The American Society of Clinical Oncology reported an annual incidence of 110 to 120 cases per 100,000 pregnancies for gestational trophoblastic disease, emphasizing the need for increased awareness. The low awareness and diagnosis rates present a significant hurdle to the gestational trophoblastic disease market's growth.

Major companies operating in the gestational trophoblastic disease market are introducing updated guidelines to enhance services. The Health Service Executive National Cancer Control Programme in Ireland launched an updated gestational trophoblastic disease guideline, aiming to provide comprehensive insights into diagnostic and management strategies. By reducing practice variation and improving the quality of care, these guidelines contribute to better outcomes for gestational trophoblastic disease patients.

Companies in the gestational trophoblastic disease market are innovating treatments, such as reproductive tissue preservation solutions, to offer reliable services. Reproductive tissue preservation solutions, preserving the viability of reproductive tissue, provide flexibility and control over family-building choices. Inception Fertility introduced HavenCryo, a long-term reproductive tissue and cryopreservation storage solution, allowing indefinite storage of eggs, sperm, and embryos. This solution proves beneficial for individuals diagnosed with gestational trophoblastic disease who need fertility preservation before undergoing treatments that may impact fertility.

Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company plc, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2022, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the gestational trophoblastic disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gestational trophoblastic disease market consists of revenues earned by entities by providing services such as gynecology services, oncology services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational trophoblastic disease market also includes sales of medications, diagnostic tools, laboratory tests, methotrexate, etoposide, cyclophosphamide, and vincristine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of gestational trophoblastic disease include hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others. A hydatidiform mole, also referred to as a molar pregnancy, is an uncommon and abnormal pregnancy condition. Treatment options for this condition include surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. These treatments are administered by various end-users such as hospitals, clinics, diagnostic centers, and others.

The gestational trophoblastic disease market research report is one of a series of new reports that provides gestational trophoblastic disease market statistics, including gestational trophoblastic disease industry global market size, regional shares, competitors with a gestational trophoblastic disease market share, detailed gestational trophoblastic disease market segments, market trends and opportunities, and any further data you may need to thrive in the gestational trophoblastic disease industry. This gestational trophoblastic disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.